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BACKGROUND: The risks of thromboembolic and hemorrhagic events in patients with atrial fibrillation
both increase with age; therefore, net clinical benefit analyses of anticoagulant treatments in the elderly
population are crucial to guide treatment. We evaluated the 1-year clinical outcomes with non-vitamin-K
antagonist and vitamin K antagonist oral anticoagulants (NOACs vs VKAs) in elderly (≥75 years) patients
with atrial fibrillation in a prospective registry setting.
METHODS: Data on 3825 elderly patients were pooled from the PREFER in AF and PREFER in AF PRO-
LONGATION registries. The primary outcome was the incidence of the net composite endpoint, including
major bleeding and ischemic cardiovascular events on NOACs (n = 1556) compared with VKAs (n = 2269).
RESULTS: The rates of the net composite endpoint were 6.6%/year with NOACs vs 9.1%/year with VKAs
(odds ratio [OR] 0.71; 95% confidence interval [CI], 0.51-0.99; P = .042). NOAC therapy was associated
with a lower rate of major bleeding compared with VKA use (OR 0.58; 95% CI, 0.38-0.90; P = .013).
Ischemic events were nominally reduced too (OR 0.71; 95% CI, 0.51-1.00; P = .050). Major bleeding with
NOACs was numerically lower in higher-risk patients with low body mass index (BMI; OR 0.50; 95% CI,
0.22-1.12; P = .07) or with age ≥85 years (OR 0.44; 95% CI, 0.13-1.49; P = .17).
CONCLUSIONS: Our real-world data indicate that, compared with VKAs, NOAC use is associated with a
better net clinical benefit in elderly patients with atrial fibrillation, primarily due to lower rates of major
bleeding. Major bleeding with NOACs was numerically lower also in higher-risk patients with low BMI
or age ≥85 years.
 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)  The American Journal of Medicine (2019)
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The prevalence of atrial fibrillation increases with age, and
advancing age predisposes to a higher risk of thromboembolic
events in patients with this arrhythmia.1 The progressive
aging of the population calls for the need of effective treat-
ment strategies in older populations with atrial fibrillation.2
The Birmingham Atrial Fibrillation Treatment of the AgedCLINICAL SIGNIFICANCE
 Compared with vitamin K antagonists,
non-vitamin K antagonist oral antico-
agulant (NOAC) use is associated with
a better net clinical benefit in elderly
patients with atrial fibrillation.
 This benefit was primarily due to lower
rates of major bleeding.
 Major bleeding with NOACs was numeri-
cally lower also in higher-risk patients
with low body mass index or age
≥85 years.Study trial demonstrated that, com-
pared with aspirin, warfarin use in
elderly patients (aged ≥75 years)
reduces atrial fibrillation-related
thromboembolic complications with-
out significantly increasing the
bleeding risk.3 Recent observational
data confirmed that even in a very
elderly population (aged ≥85 years)
with atrial fibrillation, the benefit of
oral anticoagulant (OAC) therapy on
thromboembolic events outweighs
the hemorrhagic risk.3,4
Despite this evidence, vitamin K
antagonists (VKAs) are underused
in elderly patients with atrial fibril-
lation,5,6 mainly because of safety
concerns related to a higher bleed-ing risk. In randomized trials, the benefit of the newer anti-
coagulants (non-vitamin K antagonist oral anticoagulants
[NOACs]) vs warfarin was apparent regardless of age and
maintained in elderly patients.7 However, concerns on the
utilization of NOACs in older patients may exist due to the
high prevalence of comorbid conditions, potentially influ-
encing the clinical effects of these agents.8 Thus, more evi-
dence on NOAC utilization and outcomes in older
populations with atrial fibrillation should be welcome to
date, where no extensive real-world data are currently
available. Moreover, an assessment of the net clinical bene-
fit with different anticoagulant approaches appears crucial
in elderly patients with atrial fibrillation, especially in those
at higher bleeding risk.
We therefore extracted data on elderly patients (aged
≥75 years) with atrial fibrillation from 2 large, real-world,
prospective, European registries, and compared the net clin-
ical outcome with NOACs vs VKAs over 1-year follow-up.METHODS
Patient Population and Study Design
Individual patient data were obtained from the Prevention of
thromboembolic events−European Registry in Atrial Fibrilla-
tion (PREFER in AF)9 and the Prevention of thromboembolic
events−European Registry in Atrial Fibrillation PROLONGA-
TION (PREFER in AF PROLONGATION). These registries
pooled data from 9 countries (PREFER in AF and PREFER in
AF PROLONGATION: Austria, France, Germany, Italy,
Spain, Switzerland and the United Kingdom; PREFER in AFPROLONGATION also: Belgium and The Netherlands). PRE-
FER in AF included 7228 patients in 461 centers from January
2012 to January 2014 and PREFER in AF PROLONGATION
a total of 4195 patients in 257 institutions from June 2014 to
June 2016. PREFER in AF enrolled patients regardless of
antithrombotic treatment prior to the wide adoption of the
NOACs in Europe (93% of patients on OAC received VKAsand 7% received NOACs); PREFER
in AF PROLONGATION, con-
versely, included only patients on
NOACs. In both registries there were
no explicit clinical exclusion criteria.
Patients received a clinical evaluation
at the time of enrollment and at 1-
year follow-up. On-site verification of
source data was performed at approxi-
mately 5% of the sites, randomly
selected; this verification provided
results consistent with the overall find-
ings. The registries were sponsored by
Daiichi Sankyo Europe GmbH
(Munich, Germany).
For the purpose of this study,
patients not receiving OAC were
excluded. The focus was primarilyon elderly patients (aged ≥75 years) with atrial fibrillation
who were given VKA or NOAC therapy. Patients were
included regardless of the type of VKA or NOAC.Endpoints and Definitions
The primary endpoint was a comparison, among elderly
patients, of the net composite endpoint, including both
major bleeding and ischemic cardiovascular events (acute
coronary syndrome, coronary revascularization, stroke,
transient ischemic attack [TIA], systemic embolic event),
with NOACs vs VKAs.
Definitions. Major bleeding: fatal bleeding or bleeding
into a critical organ or clinically relevant bleeding with
hemoglobin decrease ≥2 g/dL, consistent with the defini-
tion from the International Society on Thrombosis and
Haemostasis.10
Stroke: abrupt onset of a focal neurologic deficit lasting
>24 hours.
TIA: focal neurologic deficit lasting <24 hours.
Systemic embolic event: abrupt arterial insufficiency
with documentation of an arterial occlusion; venous throm-
boembolism and pulmonary embolism were also included
in this outcome measure.
Acute coronary syndrome: unstable angina or non-ST-
segment elevation myocardial infarction or ST-segment
elevation myocardial infarction. These were classified
according to the definitions available, respectively, at the
time of conduct of the 2 studies.11,12
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vention or coronary artery bypass surgery for either stable
angina or acute coronary syndrome.Statistics
Continuous variables were reported using either the mean
and standard deviation or the median and lower and upper
quartiles, as appropriate. Discrete variables were indicated
as frequency counts and percentages (n, %). Baseline char-
acteristics between the 2 treatment groups (NOACs vs
VKAs) were compared by the chi-squared test for discrete
variables and the Wilcoxon rank-sum test for continuous
variables.
Odds ratios (OR) and their confidence intervals between
patients with and without events were calculated according
to the type of OAC (NOACs vs VKAs) by logistic
regression, where outcome events were the dependent varia-
bles and NOAC treatment Yes/No was the independent vari-
able. We used the covariate adjustment method for the
propensity analysis and the propensity score adjustment for
all logistic regression models. Specific details on the covari-
ate adjustment process are reported as Supplementary Mate-
rial on Statistical Analyses (available online). Baseline
demographic/clinical characteristics reported in the Case
Report Form (n = 44) were initially used as inputs of the step-
wise procedure. A total of 20 variables were then selected via
a stepwise procedure into the propensity score and the
derived propensity score was added to all models as addi-
tional adjusting factor. Multivariate models were adjusted for
the propensity score and for the following variables:
CHA2DS2-VASc score, chronic renal failure, left atrial dila-
tation, chronic obstructive pulmonary disease, and concomi-
tant antiplatelet therapy. As a sensitivity analysis, the‘
inverse probability of treatment weight method (IPTW) was
calculated, based on the inverse of the propensity score,
where the propensity score was derived as predictor of
NOAC treatment vs VKA treatment.
The weighted net clinical benefit with NOACs vs VKAs
was also evaluated, as previously described.13,14 The 1-year
incidence of both ischemic and bleeding events was
adjusted for the estimated mortality of each event type. We
first calculated the crude incidence rate per 100 patient/years
for each type of adverse event with the 2 anticoagulant
strategies, and then the net clinical benefit was defined as
the weighted sum of these rates in the NOACs minus the
weighted sum of these rates in the VKAs group. The lower
the value of the result in this calculation, the higher the net
clinical benefit of NOACs vs VKAs was assumed to be.
All statistical analyses were performed using the SAS
version 9.3 software (SAS Institute Inc., Cary, NC), with a
2-tailed significance value set at .05.RESULTS
From the pooled populations of the 2 studies (n = 11,423), a
total of 3825 elderly patients (aged ≥75 years) representedthe object of this investigation (2269 patients on VKAs and
1556 on NOACs). Mean follow-up duration was 12 § 2
months. A flow diagram showing how the final study popu-
lation was derived is reported in the Supplementary
Figure (available online). The Supplementary Table
(available online) indicates the main characteristics of those
3825 patients included in this analysis vs elderly patients
excluded due to lack of follow-up evaluation, definitive
OAC interruption, or cross-over from an NOAC to a VKA
or vice versa. Overall, we judged the uneven distribution of
risk factors in the 2 groups as globally balanced, and there-
fore not likely to influence the results. The main baseline
demographic and clinical characteristics of the 2 treatment
groups (NOACs vs VKAs) are indicated in Table 1.
Clinical Outcome in Patients Receiving NOACs
vs VKAs
The incidence of the net composite endpoint, including
major bleeding and ischemic cardiovascular events, was
significantly lower in patients receiving NOACs (6.6 per
100 patients/year) compared with those receiving VKAs
(9.1 per 100 patients/year), with an adjusted OR of 0.71
(95% confidence interval [CI], 0.51−0.99; P = .042)
(Figure 1). Table 2 reports the absolute number of patients
with events in the 2 groups as to the net composite endpoint
and its individual components. Regarding these compo-
nents, NOAC use was associated with a 42% lower inci-
dence of major bleeding (2.7 vs 3.8 per 100 patients/year
with VKAs; adjusted OR 0.58; 95% CI, 0.38-0.90;
P = .013), mainly nongastrointestinal. Gastrointestinal hem-
orrhages were not increased in the NOACs group (adjusted
OR 0.78; 95% CI, 0.50-1.21; P = .26). There were also
nominally fewer ischemic cardiovascular events (4.1 vs 5.8
per 100 patients/year; adjusted OR 0.71; 95% CI, 0.51-
1.00; P = .050), driven by a lower occurrence of cardiac
events (acute coronary syndrome or coronary revasculariza-
tion: adjusted OR 0.63; 95% CI, 0.42-0.97; P = .045), with-
out clear differences in other vascular complications
(stroke, TIA, or systemic embolic event: adjusted OR 0.84,
95% CI, 0.53-1.34; P = .45) (Figure 1).
The results on the net clinical outcome were also ana-
lyzed according to concomitant antiplatelet therapy. The
benefit of NOACs was observed regardless of the use of
antiplatelet drugs (patients without antiplatelet treatment:
adjusted OR 0.62; 95% CI, 0.45-0.86; P = .0043; patients
on antiplatelet treatment: adjusted OR 0.75; 95% CI, 0.39-
1.42; P = .38) (P for interaction = .96). We also performed
an exploratory analysis on the net composite endpoint with
different NOACs vs VKAs; adjusted ORs were 0.73 (95%
CI, 0.46-1.15) for dabigatran, 0.58 (95% CI, 0.40-0.86) for
rivaroxaban, and 0.73 (95% CI, 0.45-1.20) for apixaban,
without significant interaction (P for interaction = .32), but
such analysis is admittedly affected by the low number of
patients (Figure 2).
The net clinical outcome was also explored in very
elderly patients (aged ≥85 years, n = 658). Here the
Table 1 Distribution of Demographic and Clinical Characteristics in Elderly Patients (Age ≥75 Years) Receiving NOACs or VKAs
Variable
NOACs
(n = 1556)
VKAs
(n = 2269) P Value
Age (years) 80.5 § 4.2 80.3 § 4.1 .23
Female sex 752 (48) 1,061 (47) .22
BMI (kg/m2) 27.0 § 4.1 27.1 § 4.4 .72
Systemic hypertension 1256 (81) 1805 (80) .48
sBP* 134.92 § 15.96 132.96 § 16.50 .0003
dBP* 77.66 § 9.70 76.75 § 10.01 .0129
Congestive heart failure* 424 (27) 776 (35) < .0001
CHA2DS2-VASc* 4.34 § 1.31 4.51 § 1.39 .0010
HAS-BLED* 2.26 § 0.98 2.38 § 1.02 .0013
EHRA score* 2.45 § 0.91 2.71 § 0.89 < .0001
Left ventricular ejection fraction* 58.7 § 9.9 56.2 § 11.7 < .0001
Prior TIA/stroke/thromboembolism 303 (20) 434 (19) .93
Vascular disease* 256 (18) 575 (27) < .0001
Chronic renal failure * 410 (27) 426 (19) < .0001
Creatinine clearance (mL/min)* 50.48 § 15.92 42.23 § 14.12 < .0001
Left atrial dilatation (diameter >40 mm)* 847 (64) 1469 (78) < .0001
Chronic obstructive pulmonary disease* 163 (11) 299 (13) .0101
Hepatic disease 17 (1.1) 34 (1.5) .2745
Concomitant antiarrhythmic drugs* 799 (51) 1304 (57) .0002
Antiplatelet therapy 213 (14) 274 (12) .1415
Type of VKA
Warfarin − 964 (43) NA
Other − 1305 (57) NA
Type of NOAC
Dabigatran 428 (27) − NA
Rivaroxaban 772 (50) − NA
Apixaban 356 (23) − NA
BMI = body mass index; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age 75 years, Diabetes mellitus, prior Stroke, TIA, or thromboembolism,
Vascular disease, Age 65-74 years, Sex category; dBP = diastolic blood pressure; EHRA = European Heart Rhythm Association; HAS-BLED = Hypertension,
Abnormal renal and liver function, Stroke, Bleeding, Labile international normalized ratio, Elderly, Drugs or alcohol; NOAC = non-vitamin K antagonist oral
anticoagulant; sBP = systolic blood pressure; TIA = transient ischemic attack; VKA = vitamin K antagonist.
*Items differing significantly (P < .05) between the NOAC and the VKA groups.Values are given as n (%) or mean § SD.
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groups (NOACs vs VKAs) (Table 3) was similar to that of
the overall elderly population. The clinical benefit of
NOAC therapy was maintained in the subgroup aged
≥85 years, where the incidence of the net composite end-
point with NOACs was not significantly lower, due to the
reduced number of patients and events (8.5 vs 9.4 per
100 patients/year with VKAs, adjusted OR 0.65; 95% CI,
0.33−1.28; P = .21). In the subgroup of patients aged
≥85 years there was a trend toward decreased major bleed-
ing with NOAC use, but this was not significant, potentially
due to the low number of patients and events (adjusted OR
0.44; 95% CI, 0.13-1.49; P = .17) (Figure 3). There was no
difference in major bleeding reduction by NOACs in
patients aged ≥85 years compared with those aged
<85 years (P for interaction = 0.50). In patients aged 75-
84 years, the adjusted OR for the net composite endpoint
was 0.71 (95% CI, 0.52-0.98; P = .043) in favor of NOACs.
We also investigated the weighted net clinical benefit. In
patients aged ≥75 years, the net clinical benefit, adjusted
for the estimated mortality of each event type, tended to
favor NOACs, but this did not achieve statisticalsignificance (¡1.74%; 95% CI, ¡4.26-0.08%; P = .055).
Consistent results were found in the subgroup with age
≥85 years (¡0.71%; 95% CI, ¡3.63-2.21; P = .39), without
difference vs patients with age <85 years (P for interac-
tion = 0.74).
The risk of major hemorrhages was then evaluated as a
function of body mass index (BMI). The effect on hemor-
rhagic outcome was maintained in patients with BMI in the
first quartile (<24.7 kg/m2; n = 1103), where, compared
with VKA use, NOAC utilization confirmed a lower occur-
rence of major bleeding (adjusted OR 0.50; 95% CI, 0.22-
1.12; P = .07) (Figure 3). ORs for major bleeding were
0.55 (95% CI, 0.19-1.51; P = .24) in the second quartile,
1.09 (95% CI, 0.42-2.86; P = .92) in the third quartile, and
0.29 (95% CI, 0.09-0.96; P = .043) in the fourth quartile.
There was no difference when evaluating the risk of hemor-
rhage across BMI categories (P for interaction = 0.67).
All the above-mentioned analyses on clinical outcomes
with NOACs vs VKAs were then performed by the IPTW
method; analyses with IPTW confirmed the results obtained
by the covariate adjustment method (see Supplementary
Material on Statistical Analyses, available online). To clarify
Figure 1 Incidence and related adjusted odds ratios (OR) for the net composite endpoint* and its individual components in
patients receiving NOACs or VKAs. CV = cardiovascular; NOACs = non-vitamin K antagonist oral anticoagulants;
VKAs = vitamin K antagonists.
*The net composite endpoint included major bleeding and ischemic cardiovascular events (cardiac events [acute coronary
syndrome, coronary revascularization] + vascular events [stroke, transient ischemic attack, systemic embolic events]).
Patti et al NOACs vs VKAs in Elderly Atrial Fibrillation Patients 753a possible confounding issue due to different countries
involved in the 2 registries, we also performed an additional
sensitivity analysis whereby patients from the 2 countries not
included in both registries (Belgium and The Netherlands,
n = 99 − 2.6% of patients) were excluded. In this sensitivity
analysis, results were consistent with the overall analysis (see
Supplementary Material on Statistical Analyses).DISCUSSION
The present analysis from 2 real-world European registries
indicated that, among elderly patients with atrial fibrilla-
tion, NOAC use was associated with improved net clinical
benefit compared with VKAs. This was mainly driven by
lower rates of major bleeding, but was also accompanied
by a nominally lower rate of ischemic events, especially
cardiac events. The better safety outcome with NOACs wasTable 2 Number of Elderly Patients (%) with Events at 1-Year Follow-U
Individual Components
Primary net composite endpoint
Major bleeding
Vascular events (Stroke/TIA/systemic embolism)
Stroke
TIA
Systemic embolism
Cardiac events (ACS, coronary revascularization)
ACS
Coronary revascularization
ACS = acute coronary syndrome; NOACs = non-vitamin K antagonist oral anticoamaintained in patients with more advanced age and in those
with low BMI.
Although there is now already a robust indication for
OAC in the prevention of atrial fibrillation-related
thromboembolic events in older populations, the real-
world penetration of anticoagulation in this setting of
patients is low.5,6 This is due to an over-representation
of VKA limitations in older populations, including drug
−drug interactions, unsatisfactory time in therapeutic
range, low adherence and perceived bleeding risk related
to the propensity of falling, reduced body weight, and
impaired renal function.5,6,15 Thus, there is an urgent
need for the implementation of stroke prevention strate-
gies alternative to VKAs to balance ischemic protection
and hemorrhagic risk in older populations.
NOACs are now available in clinical practice. A pooled
analysis of phase III studies on NOACs in patients withp in the 2 Groups for the Primary Net Composite Endpoint and its
NOACs VKAs
n = 1556 n = 2269
99 (6.6) 207 (9.1)
40 (2.7) 85 (3.8)
37 (2.5) 67 (3.0)
14 (0.9) 21 (0.9)
20 (1.3) 36 (1.6)
5 (0.3) 13 (0.6)
27 (1.8) 69 (3.0)
20 (1.3) 37 (1.6)
19 (1.2) 47 (2.1)
gulants; TIA = transient ischemic attack; VKAs = vitamin K antagonists.
Figure 2 Analysis on the net composite endpoint with different NOACs vs VKAs. NOACs = non-vitamin K antag-
onist oral anticoagulants; OR = odds ratio; SEE = systemic embolic events; TIA = transient ischemic attack;
VKAs = vitamin K antagonists.
754 The American Journal of Medicine, Vol 132, No 6, June 2019atrial fibrillation found no interaction between clinical ben-
efit of these agents vs warfarin and age.7,16-19 Moreover, in
a meta-analysis on elderly patients with atrial fibrillation,Table 3 Distribution of Demographic and Clinical Characteristics in Ve
Variable NOACs
(n = 296)
Age (years) 87.3 § 2.2
Female sex 173 (58)
BMI (kg/m2) 26.1 § 3.9
Systemic hypertension 244 (83)
sBP* 136.13 § 1
dBP 76.67 § 9.3
Congestive heart failure* 86 (29)
CHA2DS2-VASc 4.58 § 1.34
HAS-BLED 2.53 § 1.01
EHRA score* 2.59 § 0.90
Left ventricular ejection fraction* 58.4 § 10.0
Prior TIA/stroke/thromboembolism 76 (26)
Vascular disease* 50 (19)
Chronic renal failure* 106 (36)
Creatinine clearance* 42.79 § 13
Left atrial dilatation (diameter >40 mm)* 169 (68)
Chronic obstructive pulmonary disease* 28 (10)
Hepatic disease 3 (1.0)
Concomitant antiarrhythmic drugs 160 (54)
Antiplatelet therapy 49 (17)
Type of VKA
Warfarin −
Other −
Type of NOAC
Dabigatran 76 (26)
Rivaroxaban 138 (46)
Apixaban 82 (28)
Values are given as n (%) or mean § SD.
BMI = body mass index; CHA2DS2-VASc = Congestive heart failure, Hypertensio
Vascular disease, Age 65-74 years, Sex category; dBP = diastolic blood pressure
Abnormal renal and liver function, Stroke, Bleeding, Labile international normal
anticoagulant; sBP = systolic blood pressure; TIA = transient ischemic attack; VKA
*Items significantly differing between the 2 populations investigated.NOACs were more effective than conventional therapy in
preventing thromboembolic events, without bleeding
excess.20 However, available data on NOACs in olderry Elderly Patients (Age ≥85 Years) Receiving NOACs or VKAs
VKAs
(n = 362) P Value
87.2 § 2.4 .21
197 (54) .30
25.6 § 3.9 .19
282 (79) .23
5.73 133.17 § 17.75 .0231
1 75.30 § 10.44 .1444
156 (44) < .001
4.72 § 1.45 .22
2.40 § 1.04 .14
2.84 § 0.88 < .001
56.0 § 12.4 .020
79 (22) .26
103 (30) .001
85 (24) < .001
.16 36.09 § 11.52 .0023
242 (81) < .001
54 (15) .033
6 (1.7) .4748
192 (53) .7950
47 (13) .1968
150 (41) NA
212 (59) NA
− NA
− NA
− NA
n, Age 75 years, Diabetes mellitus, prior Stroke, TIA, or thromboembolism,
; EHRA = European Heart Rhythm Association; HAS-BLED = Hypertension,
ized ratio, Elderly, Drugs or alcohol; NOAC = non-vitamin K antagonist oral
= vitamin K antagonist.
Figure 3 Odds ratios (OR) for major bleeding with NOACs vs VKAs in elderly patients (aged
≥75 years), elderly patients with BMI <24.7 kg/m2, and very elderly patients (aged ≥85 years).
BMI = body mass index; NOACs = non-vitamin K antagonist oral anticoagulants; VKAs = vita-
min K antagonists.
Patti et al NOACs vs VKAs in Elderly Atrial Fibrillation Patients 755populations with atrial fibrillation are essentially derived
from subgroup analyses of randomized studies that,
although often prespecified, have included low numbers of
patients. Moreover, various conditions at high prevalence
in older populations may impact on the efficacy, and mainly
on the safety of NOACs, for example, hypoalbuminemia,
fluctuations of renal function, low body weight, and pro-
pensity to gastrointestinal bleeding. Thus, real-world data
on the topic are needed. A small observational study
showed low event rates with NOACs in elderly patients
switched from other antithrombotic treatments.21 Indeed,
real-world evidence focused on the net clinical outcome of
NOAC utilization in advancing age populations is relevant
to address current concerns and better define the specific
role of such agents in this expanding setting of patients.
The analysis here presented is consistent with this need.
The present study pooled data from 2 multicenter, real-
world registries (PREFER in AF and PREFER in AF PRO-
LONGATION) and evaluated the net clinical benefit at 1
year with NOACs vs VKAs in elderly patients with atrial
fibrillation. NOAC use led to a significantly lower inci-
dence of the net composite endpoint, including major
bleeding and cardiovascular events, compared with VKAs.
This was primarily driven by a 42% lower rate of major
bleeding. Consistent results were observed in the analysis
on the weighted net clinical benefit, adjusted for the esti-
mated mortality of each adverse event type. NOACs were
prescribed at the time of the PREFER in AF registries toless-sick patients. Our results on outcome with the 2 antico-
agulant approaches needed, therefore, to be adjusted for
possible confounders, although the nonrandomized nature
of the source data preclude absolute certainty on conclu-
sions to be derived from this approach. Of note, this better
safety of NOACs was regardless of concomitant antiplatelet
therapy; the higher bleeding risk carried by the concomitant
antiplatelet therapy and the high prevalence of the associa-
tion OAC plus antiplatelet treatment underscored the need
to limit this combination therapy to situations where it is
really needed.22 Elderly patients are at higher risk of gastro-
intestinal bleeding, and in randomized trials an increased
incidence of gastrointestinal bleeding was observed with
rivaroxaban, high-dose dabigatran, and high-dose edoxaban
vs warfarin.19,23 Importantly, no excess of gastrointestinal
hemorrhages in elderly patients receiving the newer antico-
agulants has emerged from our analysis. Our findings are in
line with recent real-world data from Taiwan indicating
that NOACs use in patients aged ≥90 years was associated
with lower rates of intracranial hemorrhage and similar
stroke rates as warfarin.24
In the NOAC group we also observed a significantly lower
occurrence of ischemic cardiovascular complications, mainly
cardiac events. Although our analysis was adjusted for avail-
able variables that could potentially influence the risk of car-
diovascular events, this finding may still be due to
confounders not captured by the risk variables collected in
the registries. Of note, in the ROCKET-AF trial the rates of
756 The American Journal of Medicine, Vol 132, No 6, June 2019cardiac events were lower in patients assigned to
rivaroxaban compared with warfarin,25 consistent with our
findings. The apparently better coronary protection with
NOACs in our study is intriguing, but has to be taken with a
word of caution and would merit confirmation.
We also evaluated the clinical outcome with the 2 antico-
agulant strategies in subgroups at even higher bleeding risk,
such as elderly patients with concomitant low BMI and very
elderly patients (aged ≥85 years). The improved safety out-
come with NOACs was maintained also in patients with the
lowest BMI, where the occurrence of major bleeding with
the newer agents was 50% lower. Moreover, we found that
very elderly patients, when receiving NOACs instead of
VKAs, had a 56% relative reduction of major bleeding.
Our study has strengths and limitations. Both registries
were prospective investigations on atrial fibrillation patients
receiving a complete baseline assessment and a planned fol-
low-up visit at 1 year, with accurate evaluation of treat-
ments and endpoints. Channeling bias or bias in patient
enrollment and treatment decision cannot be excluded,
although recruitment of consecutive patients at each center
was mandatory. No specific information on adherence and
persistence with therapy was available, although compli-
ance was assessed during follow-up visits and those few
patients who had definitely stopped OAC were excluded.
No data on international normalized ratio (INR) control in
VKA-treated patients were available. However, INR con-
trol was assessed by collecting the last 3 INR measurements
prior to enrollment; these pre-enrollment, repeated, INR
detections may be inadequate due to the large INR variabil-
ity over time, although these measurements were reported
to be a reliable proxy for the time in therapeutic range.26
An adequate INR control (ie, at least 2 of 3 INR values in
the therapeutic range) was demonstrated in 72% of the
overall population. Only cardiology institutions partici-
pated in the registries, and therefore, very frail patients (ie,
residents in nursing homes with multiple comorbidities and
major functional disabilities) were not included. Moreover,
no outcome data on patients receiving edoxaban may be
obtained. Finally, our results were adjusted for possible
confounding variables, but residual confounding cannot be
excluded; nevertheless, an estimation of the impact of a
potential unmeasured confounder on the outcome measures
suggests that it is unlikely such a confounder alone could
have driven the results.
In conclusion, our study shows that, compared with
VKAs, NOAC use is associated with a lower incidence of
major bleeding in elderly patients with atrial fibrillation.
Protection from cardiovascular events was also more prom-
inent with the NOACs, with the safety benefits providing
the greatest contribution to the improved net clinical out-
come observed in the NOAC group. Moreover, NOAC uti-
lization overcomes intrinsic limitations of VKAs that are
highly prevalent in older populations. Thus, logical consid-
erations and evidence-based data both make NOACs the
anticoagulant drugs of choice in elderly patients, here
achieving the best net clinical benefit.ACKNOWLEDGMENTS
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757.e1 The American Journal of Medicine, Vol 132, No 6, June 2019DETAILS ON THE COVARIATE ADJUSTMENT PROCESSThe following baseline demographic/clinical characteristics reported in the Case Report Form (n = 44) were initially used as
inputs of the stepwise procedure:
1 AF type
2 Maximum EHRA score
3 Antiarrhythmic drug
4 Vascular disease
5 Chronic renal insufficiency
6 Left atrial dilatation
7 Previous other ischemic-thromboembolic event
8 Arterial hypertension
9 HAS-BLED score10 Age
11 Cardioversion
12 Previous ischemic stroke
13 Previous ischemic stroke/TIA/other thromboembolic event
14 Previous TIA
15 Reduced left ventricular function
16 Heart failure
17 Antiplatelet drug
18 Dyslipidemia
19 Coronary heart disease (CHD) OR Peripheral artery disease (PAD) OR myocardial infarction (MI)
20 Systolic blood pressure
21 Diastolic blood pressure
22 Gender
23 Ablation (pulmonary vein isolation)
24 Previous myocardial infarction
25 Chronic hepatic disease
26 Diabetes mellitus
27 Obesity (BMI >30)
28 BMI
29 Chronic obstructive pulmonary disease
30 Current smoker
31 Previous smoker
32 Any smoking (current or previous)
33 Hyperthyroidism
34 Heart valve dysfunction
35 Coronary heart disease (CHD)
36 Chronic heart insufficiency
37 Reduced left ventricular function
38 Peripheral artery disease (PAD)
39 Left ventricular ejection fraction
40 Current heart rhythm
41 CHA2DS2-VASc score
42 CHADS2 score
43 Alcohol abuse
44 Weight
Patti et al NOACs vs VKAs in Elderly Atrial Fibrillation Patients 757.e2Of course, not all those 44 baseline characteristics were selected via stepwise procedure into the propensity score (PS). The
following 20 variables were selected via a stepwise procedure into the PS:
Summary of Stepwise SelectionEffectStep Entered Removed DF Number In Score Chi-Squared Wald Chi-Squared Pr > ChiSq1 AF type 3 1 218.9979 < .0001
2 Maximum EHRA score 1 2 103.2338 < .0001
3 Antiarrhythmic drug 1 3 46.6609 < .0001
4 Vascular disease 1 4 48.1339 < .0001
5 Chronic renal insufficiency 1 5 50.9278 < .0001
6 Left atrial dilatation 1 6 38.6998 < .0001
7 Previous other ischemic-thromboem-
bolic event
1 7 33.7989 < .00018 Arterial hypertension 1 8 18.5104 < .0001
9 HAS-BLED score 1 9 37.1147 < .000110 Age 1 10 19.8497 < .0001
11 Cardioversion 1 11 14.6368 .0001
12 Previous ischemic stroke 1 12 8.8477 .0029
13 Previous ischemic stroke/TIA/other
thromboembolic event
1 13 10.7021 .001114 Previous TIA 1 14 23.7044 < .0001
15 Reduced left ventricular function 1 15 7.8787 .0050
16 Heart failure 1 16 14.2966 .0002
17 Antiplatelet drug 1 17 7.7806 .0053
18 Dyslipidaemia 1 18 4.9385 .0263
19 Coronary heart disease (CHD) OR
Peripheral artery disease (PAD) or
myocardial infarction (MI)1 19 5.2008 .022620 Systolic blood pressure 1 20 5.2559 .0219The PS (conditional probability of being assigned to a
NOAC vs being assigned to VKA at an observed set of
covariates) was the following:
PROPENSITY SCORE (PS), estimating NOAC treat-
ment vs VKA treatment probability =
+ AF type (Paroxysmal 0, Persistent -0.3147, Long-
standing persistent -1.1332, Permanent -0.9997)
+ Maximum EHRA score ¡0.3264
+ Antiarrhythmic drug ¡0.3626
+ Vascular disease ¡0.6972
+ Chronic renal failure 0.9145
+ Left atrial dilatation ¡0.4547
+ Previous other ischemic-thromboembolic event 1.1345
+ Arterial hypertension 0.5108
+ HAS-BLED score ¡0.3542
+ Age 0.0133
+ Cardioversion ¡0.2551
+ Previous ischemic stroke 1.2111
+ Previous ischemic stroke/TIA/other thromboembolic
event ¡1.1653
+ Previous TIA 0.8340
+ Reduced left ventricular function ¡0.5613
+ Heart failure 0.4150
+ Antiplatelet therapy 0.3093
+ Dyslipidemia ¡0.1603+ Coronary heart disease (CHD) or peripheral arterial
disease (PAD) or myocardial infarction (MI) 0.2643
+ Systolic blood pressure 0.00426
The probability to be treated by NOACs was
PS_prob=1/[1+exp(¡PSscore)]. The abovementioned
derived PS was added to all models as additional adjusting
factor. Multivariate models were not adjusted for all 44
baseline characteristics or for those 20 baseline characteris-
tics selected into the PS.
Based on a combination of medical reasons and statisti-
cal analyses of all possible confounding effects from all
baseline characteristics, the following variable were
selected as adjusting factors: CHA2DS2-VASc score,
chronic renal failure, left atrial dilatation, chronic obstruc-
tive pulmonary disease, concomitant antiplatelet therapy.
Interaction of each of these parameters with treatment
effect (NOACs vs VKAs) was assessed, but none interac-
tion was significant or remarkable.
Regression adjustment was done using PROC LOGIS-
TIC, where the treatment effect (NOACs vs VKAs) for the
abovementioned covariates was included into the model:
PROC LOGISTIC data=AF_registries; Class trt (REF=’
VKAs’) renal_failure (REF=’ No’) left_atrial_dilat
(REF=’ No’) COPD (REF=’ No’) antiplatelets (REF=’
No’); Model FU_outcome (event=’Yes’) = trt CHADSVASc
757.e3 The American Journal of Medicine, Vol 132, No 6, June 2019renal_failure left_atrial_dilat COPD antiplatelets / link=-
logit rsquare; run.
Multivariate models were adjusted for the PS and for the
following variables: CHA2DS2-VASc score, chronic renal
failure, left atrial dilatation, chronic obstructive pulmonary
disease and concomitant antiplatelet therapy. Thus, after
adding the PS into adjustment factors, the real coefficient
of each adjustment factor is a sum of its coefficient at the
PS and its coefficient as additional adjusting factor.INVERSE PROBABILITY OF TREATMENT
WEIGHTING ANALYSIS
The inverse probability of treatment weight (IPTW) was
calculated as the inverse of the propensity score (PS)
(Hogan, J.W., Lancaster, T. 2004. ”Instrumental variable
and propensity weighting for causal inference fromIPTW Odds Ratio Estimate
Point Es
Net composite endpoint (age ≥75 years) 0.727
Major bleeding (age ≥75 years) 0.772
Ischemic cardiovascular events (age ≥75 years) 0.892
Ischemic cardiac events (age ≥75 years) 0.896
Ischemic vascular events (age ≥75 years) 0.859
Gastro-intestinal bleeding (age ≥75 years) 0.730
Net composite endpoint (age ≥75 years) in patients not
receiving antiplatelet therapy
0.734
Net composite endpoint (age ≥75 years) in patients
receiving antiplatelet therapy
0.683
Net composite endpoint (age ≥85 years) 0.376
Major bleeding (age ≥85 years) 0.249
Major bleeding (age ≥75 years in the first BMI quartile) 0.700
Major bleeding (age ≥75 years in the second BMI
quartile)
0.429
Major bleeding (age ≥75 years in the third BMI quartile) 1.353
Major bleeding (age ≥75 years in the fourth BMI
quartile)
0.545
Net composite endpoint (age ≥75 years, rivaroxaban vs
VKAs)
0.663
Net composite endpoint (age ≥75 years, dabigatran vs
VKAs)
0.873
Net composite endpoint (age ≥75 years, apixaban vs
VKAs)
0.738
Weighted net clinical benefit (age ≥75 years)
Weighted net clinical benefit (age ≥85 years)longitudinal observational studies”. Statistical Methods in
Medical Research 13: 17-48), according to the propensity
PS_prob to be on NOACs vs VKAs. For those patients who
were not on NAOCs, the PS would be 1- PS_prob and the
PS weight would be the inverse of 1- PS_prob. According
to the abovementioned paper (Hogan JW, et al):
 If trt=’ NOACs’ then PS_weight=1/ PS_prob;
 If trt=’ VKAs’ then PS_weight=1/(1- PS_prob);
This PS-weighted logistic linear regression model using
PROC LOGISTIC procedure was then fitted to compare
NOACs use on the outcome events vs VKAs use effect:
proc logistic data=AF_registries; Class trt (REF=’
VKAs’); Model FU_outcome (event=’Yes’) = trt / expb
link=logit rsquare; Weight PS_weight; run
Results of the IPTW analysis:s − NOACs vs VKAs
timate 95% Wald Confidence Limits P Value
0.595 0.889 .0019
0.576 1.034 .0824
0.759 1.048 .1630
0.581 1.383 .6211
0.727 1.015 .0742
0.479 1.113 .1435
0.587 0.917 .0065
0.430 1.085 .1063
0.216 0.656 .0006
0.085 0.726 .0109
0.413 1.187 .1853
0.225 0.819 .0103
0.806 2.271 .1248
0.300 0.991 .0465
0.517 0.851 .0012
0.659 1.156 .3441
0.529 1.030 .0744
.0367
.0669
Patti et al NOACs vs VKAs in Elderly Atrial Fibrillation Patients 757.e4Additional sensitivity analysis on 3726 patients, whereby
excluded (Belgium and The Netherlands, n = 99 patients).patients from countries not included in both registries wereCovariate Adjustment: Odds Ratio Estimates − NOACs (n = 1457) vs VKAs (n = 2269)
Point Estimate 95% Wald Confidence Limits P Value
Net composite endpoint (age ≥75 years) 0.66 0.50 0.89 .006
Major bleeding (age ≥75 years) 0.51 0.32 0.81 .004
Ischemic cardiovascular events (age ≥75 years) 0.72 0.51 1.00 .050
Ischemic cardiac events (age ≥75 years) 0.64 0.32 1.29 .212
Ischemic vascular events (age ≥75 years) 0.67 0.52 0.86 .002
Gastro-intestinal bleeding (age ≥75 years) 0.50 0.25 0.98 .043
Net composite endpoint (age ≥75 years) in patients not
receiving antiplatelet therapy
0.66 0.48 0.91 .012
Net composite endpoint (age ≥75 years) in patients
receiving antiplatelet therapy
0.69 0.36 1.36 .285
Net composite endpoint (age ≥85 years) 0.67 0.34 1.32 .246
Major bleeding (age ≥85 years) 0.55 0.19 1.58 .228
Major bleeding (age ≥75 years in the first BMI quartile) 0.43 0.18 1.04 .062
Major bleeding (age ≥75 years in the second BMI
quartile)
0.43 0.17 1.12 .085
Major bleeding (age ≥75 years in the third BMI quartile) 1.30 0.44 3.82 .635
Major bleeding (age ≥75 years in the fourth BMI
quartile)
0.46 0.18 1.23 .122
Weighted net clinical benefit (age ≥75 years) .049
Weighted net clinical benefit (age ≥85 years) .488
Supplementary Table Demographic and Clinical Characteristics of Elderly Patients Included in the Study vs Elderly Patients Excluded
from the Analysis
Variable
Patients Included
(n = 3852)
Patients Excluded
(n = 1079) P Value
Age (years) 80.4 § 4.1 81.1 § 4.4 < .0001
Female sex 1813 (47) 560 (52) .0082
BMI (kg/m2) 27.1 § 4.3 27.0 § 4.4 .2582
Systemic hypertension 3061 (80) 862 (81) .8349
sBP 133.68 § 16.34 133.29 § 18.29 .1444
dBP 77.07 § 9.91 76.81 § 10.72 .4667
Congestive heart failure 1200 (32) 298 (29) .0468
CHA2DS2-VASc 4.44 § 1.36 4.44 § 1.35 .7961
HAS-BLED 2.34 § 1.01 2.53 § 0.98 < .0001
EHRA Score 2.61 § 0.91 2.67 § 0.90 .0544
Left ventricular ejection fraction 57.2 § 11.1 56.7 § 11.0 .0824
Prior TIA/stroke/thromboembolism 737 (19) 161 (15) .0021
Vascular disease 831 (24) 226 (25) .5097
Chronic renal failure 836 (22) 235 (22) .9538
Left atrial dilatation (diameter >40 mm) 2316 (72) 603 (65) < .0001
Chronic obstructive pulmonary disease 462 (12) 150 (14) .0729
Values are given as n (%) or mean § SD.
BMI = body mass index; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age 75 years, Diabetes mellitus, prior Stroke, TIA, or thromboembolism,
Vascular disease, Age 65-74 years, Sex category; dBP = diastolic blood pressure; EHRA = European Heart Rhythm Association; HAS-BLED = Hypertension,
Abnormal renal and liver function, Stroke, Bleeding, Labile international normalized ratio, Elderly, Drugs or alcohol; sBP = systolic blood pressure;
TIA = transient ischemic attack.
*Items differing significantly (P < .05).
Supplementary Figure Flow diagram showing how the final study population was derived from the 2 registries.
NOACs = non-vitamin K antagonist oral anticoagulants; OAC = oral anticoagulant therapy; VKAs = vitamin K antagonists.
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